PL2593791T3 - Domeny wiążące białko stabilizujące funkcjonalne stany konformacyjne gcpr i ich zastosowania - Google Patents

Domeny wiążące białko stabilizujące funkcjonalne stany konformacyjne gcpr i ich zastosowania

Info

Publication number
PL2593791T3
PL2593791T3 PL11732498T PL11732498T PL2593791T3 PL 2593791 T3 PL2593791 T3 PL 2593791T3 PL 11732498 T PL11732498 T PL 11732498T PL 11732498 T PL11732498 T PL 11732498T PL 2593791 T3 PL2593791 T3 PL 2593791T3
Authority
PL
Poland
Prior art keywords
gpcrs
binding domains
protein binding
conformational states
functional conformational
Prior art date
Application number
PL11732498T
Other languages
English (en)
Inventor
Jan Steyaert
Els Pardon
Toon Laeremans
Brian Kobilka
Juan Fung
Søren Rasmussen
Original Assignee
Vib Vzw
Vrije Universiteit Brussel
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw, Vrije Universiteit Brussel, The Board Of Trustees Of The Leland Stanford Junior University filed Critical Vib Vzw
Publication of PL2593791T3 publication Critical patent/PL2593791T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
PL11732498T 2010-07-16 2011-07-18 Domeny wiążące białko stabilizujące funkcjonalne stany konformacyjne gcpr i ich zastosowania PL2593791T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39978110P 2010-07-16 2010-07-16
GBGB1014715.5A GB201014715D0 (en) 2010-09-06 2010-09-06 Nanobodies stabilizing functional conformational states of GPCRS
EP11732498.8A EP2593791B1 (en) 2010-07-16 2011-07-18 Protein binding domains stabilizing functional conformational states of gpcrs and uses thereof

Publications (1)

Publication Number Publication Date
PL2593791T3 true PL2593791T3 (pl) 2017-08-31

Family

ID=43037319

Family Applications (5)

Application Number Title Priority Date Filing Date
PL23185997.6T PL4273549T3 (pl) 2010-07-16 2011-07-18 Domeny wiążące białko, stabilizujące funkcjonalne stany konformacyjne gpcr i ich zastosowanie
PL11732498T PL2593791T3 (pl) 2010-07-16 2011-07-18 Domeny wiążące białko stabilizujące funkcjonalne stany konformacyjne gcpr i ich zastosowania
PL11734078T PL2593792T3 (pl) 2010-07-16 2011-07-18 Domeny wiążące białko stabilizujące funkcjonalne stany konformacyjne gpcr i ich zastosowanie
PL19169005T PL3557255T3 (pl) 2010-07-16 2011-07-18 Domeny wiążące białko stabilizujące funkcjonalne stany konformacyjne GPCR i ich zastosowanie
PL19169004T PL3557254T3 (pl) 2010-07-16 2011-07-18 Domeny wiążące białko stabilizujące funkcjonalne stany konformacyjne GPCR i ich zastosowania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL23185997.6T PL4273549T3 (pl) 2010-07-16 2011-07-18 Domeny wiążące białko, stabilizujące funkcjonalne stany konformacyjne gpcr i ich zastosowanie

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL11734078T PL2593792T3 (pl) 2010-07-16 2011-07-18 Domeny wiążące białko stabilizujące funkcjonalne stany konformacyjne gpcr i ich zastosowanie
PL19169005T PL3557255T3 (pl) 2010-07-16 2011-07-18 Domeny wiążące białko stabilizujące funkcjonalne stany konformacyjne GPCR i ich zastosowanie
PL19169004T PL3557254T3 (pl) 2010-07-16 2011-07-18 Domeny wiążące białko stabilizujące funkcjonalne stany konformacyjne GPCR i ich zastosowania

Country Status (15)

Country Link
US (16) US20130137856A1 (pl)
EP (7) EP4273549B1 (pl)
JP (4) JP6302248B2 (pl)
CN (1) CN103180734B (pl)
BR (1) BR112013001180B1 (pl)
CA (1) CA2805560C (pl)
DK (5) DK3557255T3 (pl)
ES (5) ES2613532T3 (pl)
FI (1) FI4273549T3 (pl)
GB (1) GB201014715D0 (pl)
HR (3) HRP20170201T1 (pl)
HU (2) HUE070205T2 (pl)
PL (5) PL4273549T3 (pl)
PT (5) PT3557254T (pl)
WO (2) WO2012007593A1 (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
NO2723764T3 (pl) 2011-09-15 2018-05-26
EP3321257A1 (en) 2012-02-23 2018-05-16 Vanderbilt University Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
CN103509115B (zh) * 2012-06-21 2016-03-23 中国科学院上海生命科学研究院 人胱抑素c纳米抗体及其应用
EP2867674B1 (en) 2012-06-28 2018-10-10 UCB Biopharma SPRL A method for identifying compounds of therapeutic interest
WO2014035829A1 (en) * 2012-08-31 2014-03-06 Vanderbilt University Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators
AU2014211355B2 (en) * 2013-01-30 2017-07-13 Vib Vzw Novel chimeric polypeptides for screening and drug discovery purposes
AU2014214054B2 (en) 2013-02-05 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Muscarinic acetylcholine receptor binding agents and uses thereof
WO2014124020A1 (en) 2013-02-05 2014-08-14 The Board Of Trustees Of The Leland Stanford Junior University Method for selecting agents that bind to transmembrane receptors in a conformationally-selective manner
WO2014153044A1 (en) * 2013-03-14 2014-09-25 Temple University Of The Commonwealth System Of Higher Education Treatment of patients with hyponatremia and cardiac disease
KR102163529B1 (ko) 2013-06-28 2020-10-12 엑스-바디 인코포레이티드 표적 항원 발견, 표현형 선별 및 표적 세포 특이성 표적 에피토프를 규명하기 위한 그의 용도
EP3036233A1 (en) 2013-08-23 2016-06-29 Vanderbilt University Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
CN103454413B (zh) * 2013-09-04 2015-03-11 吉日木图 双峰驼特异性抗体制备及免疫检测方法
CA2924879C (en) 2013-09-23 2023-01-10 X-Body, Inc. Methods and compositions for generation of binding agents against cell surface antigens
PT3194976T (pt) 2014-07-22 2020-07-03 Univ Brussel Vrije Métodos para selecionar agentes que estabilizam complexos proteicos
GB201601690D0 (en) 2016-01-29 2016-03-16 Heptares Therapeutics Ltd G proteins
DE102016116391B3 (de) * 2016-09-01 2018-02-01 Gea Mechanical Equipment Gmbh Verfahren zum Überwachen einer Schneckenzentrifuge
WO2018208877A1 (en) * 2017-05-09 2018-11-15 Yale University Basehit, a high-throughput assay to identify proteins involved in host-microbe interaction
CN110869362A (zh) * 2017-05-12 2020-03-06 国立研究开发法人理化学研究所 A类gpcr结合性化合物改性体
CN107423555B (zh) * 2017-06-09 2020-06-30 王�忠 一种探索药物新适应症的方法
JP7347899B2 (ja) * 2017-08-09 2023-09-20 オリオンズ バイオサイエンス インコーポレイテッド Ｃｄ８結合物質
CN113501881B (zh) * 2017-09-27 2023-07-28 北京大学 融合蛋白
EP3691684A1 (en) * 2017-10-02 2020-08-12 VIB vzw Compounds to inhibit bacterial s-layer protein assembly
KR20250070615A (ko) 2017-10-31 2025-05-20 브이아이비 브이지더블유 신규한 항원-결합 키메라 단백질 및 이의 방법 및 용도
KR102485253B1 (ko) * 2017-11-10 2023-01-06 현대자동차주식회사 대화 시스템 및 그 제어방법
WO2020035741A2 (en) * 2018-07-05 2020-02-20 Novobind Livestock Therapeutics Inc. Antibodies against disease causing agents of poultry and uses thereof
CN110759998A (zh) * 2018-07-27 2020-02-07 深圳康体生命科技有限公司 一种gfp抗体制备方法及其dna序列
EP3963329A1 (en) 2019-04-29 2022-03-09 Confo Therapeutics N.V. Screening methods and assays for use with transmembrane proteins, in particular with gpcrs
US20220268706A1 (en) * 2019-05-01 2022-08-25 Commonwealth Scientific And Industrial Research Organisation Immunosensor
CN113891896B (zh) * 2019-05-07 2023-09-26 庄亚(北京)生物科技有限公司 单域抗体融合蛋白及其在止血中的应用
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
US20240139302A1 (en) 2020-02-21 2024-05-02 Origimm Biotechnology Gmbh Propionibacterium acnes prophylactic and therapeutic immune treatment
US20230218777A1 (en) * 2020-05-28 2023-07-13 The Board Of Trustees Of The Leland Stanford Junior University Aerosolized mucus-tethering nanobodies to protect against viral and microbial contamination in closed and semi-enclosed spaces
AU2021350174A1 (en) * 2020-09-25 2023-05-04 The Board Of Trustees Of The Leland Stanford Junior University Potent binding agents for activation of the hedgehog signaling pathway
CN112843222B (zh) * 2021-01-21 2023-01-31 暨南大学 Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用
CN112851811B (zh) * 2021-01-28 2022-08-09 姜国胜 一种cd44v6纳米抗体及其作为白血病研究试剂的应用
US12282027B2 (en) 2021-02-19 2025-04-22 University Of South Florida High-throughput NMR approach for in-membrane protein ligand screening
WO2022258437A1 (en) * 2021-06-07 2022-12-15 Paul Scherrer Institut Quantification of protein-protein interaction of membrane proteins using high-mass mass spectrometry
CN113717874B (zh) * 2021-09-27 2023-04-11 四川大学 一种耐高温、耐高糖的酿酒酵母菌株及其构建方法和应用
AU2023229091A1 (en) * 2022-03-04 2024-09-12 Coagulant Therapeutics Corporation Camelid antibodies against activated protein c and uses thereof
WO2023201173A2 (en) * 2022-04-11 2023-10-19 Vanderbilt University Anti-cox-2 nanobodies for endoscopic visualization of colorectal adenomas
WO2024192704A1 (en) * 2023-03-22 2024-09-26 Biofront Therapeutics (Beijing) Co., Ltd. Nanobodies that bind to gprc5d and uses thereof
CN116813781B (zh) * 2023-07-29 2024-01-12 十堰市太和医院（湖北医药学院附属医院） 一种靶向β2AR的纳米抗体及其制备方法和应用
WO2025100417A1 (ja) * 2023-11-06 2025-05-15 株式会社ダイセル Ａａｖのフルカプシドに対するアフィニティポリペプチド
CN118324905B (zh) * 2024-06-14 2024-09-03 广州明药科技有限公司 抗人β2微球蛋白的纳米抗体及其应用
CN118894930A (zh) * 2024-07-31 2024-11-05 演生潮(北京)生物科技有限公司 一种基于生物学活性评价的纳米抗体快速筛查方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU639671B2 (en) * 1988-10-03 1993-08-05 Scripps Clinic And Research Foundation Monoclonal antibodies against receptor-induced binding sites
DE68929127T2 (de) 1988-10-03 2000-05-31 The Scripps Research Institute, La Jolla Monoklonale antikörper gegen rezeptor-induzierte bindungsstellen auf liganden, die an proteine der cytoadhesin-superfamilie binden
DK1498427T3 (da) 1992-08-21 2010-04-26 Univ Bruxelles Immunoglobuliner, som ikke har lette kæder
EP1051493A2 (en) 1998-01-26 2000-11-15 Unilever Plc Method for producing antibody fragments
DK1144616T4 (da) 1999-01-19 2009-03-30 Unilever Nv Fremgangsmåde til fremstilling af antistoffragmenter
WO2001090190A2 (en) 2000-05-26 2001-11-29 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
US7208279B2 (en) 2001-03-14 2007-04-24 Caden Biosciences, Inc. Method for identifying inhibitors of G protein coupled receptor signaling
US7294472B2 (en) 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
WO2002086460A1 (en) 2001-04-20 2002-10-31 Consensus Pharmaceuticals, Inc. Methods for identifying ligands of g-protein-coupled receptors
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20030129649A1 (en) 2001-04-24 2003-07-10 Kobilka Brian K. Conformational assays to detect binding to G protein-coupled receptors
WO2004035614A1 (en) * 2001-07-11 2004-04-29 Karo Bio Ab Synthetic or partially purified peptides which can bind to specific subunits of g proteins and uses thereof
WO2003025020A1 (fr) 2001-09-13 2003-03-27 Institute For Antibodies Co., Ltd. Procede pour creer une banque d'anticorps de chameaux
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
DE60329627D1 (de) 2002-12-31 2009-11-19 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
US9029097B2 (en) 2005-02-16 2015-05-12 Universite De Montreal Biosensors for monitoring receptor-mediated G-protein activation
EP2631652A1 (en) * 2005-04-05 2013-08-28 Corning Incorporated Label free biosensor
AU2006301426A1 (en) * 2005-10-11 2007-04-19 Ablynx N.V. NanobodiesTM and polypeptides against EGFR and IGF-IR
BRPI0708175A2 (pt) * 2006-02-22 2011-05-17 Philogen Spa marcadores de tumores vasculares
EP2557090A3 (en) * 2006-12-19 2013-05-29 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
GB2456235B8 (en) 2007-03-22 2009-12-09 Heptares Therapeutics Ltd Stable beta-adrenergic receptor mutants
EP2152752B1 (en) * 2007-05-15 2017-11-08 F. Hoffmann-La Roche AG Antibody directed to g protein coupled receptors (gpcr)
WO2009051633A1 (en) * 2007-10-15 2009-04-23 The Board Of Trustees Of The Leland Stanford Junior University Gpcr crystalization method using an antibody
GB0724860D0 (en) * 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
MX2010012518A (es) * 2008-05-16 2010-12-06 Ablynx Nv Secuencias de aminoacidos dirigidas contra cxcr4 y otros receptores acoplados a proteina g y compuestos que comprenden los mismos.
ES2713864T3 (es) * 2008-06-05 2019-05-24 Ablynx Nv Secuencias de aminoácidos dirigidas contra proteínas de la envuelta de un virus y polipéptidos que comprenden las mismas para el tratamiento de enfermedades virales
US20110166076A1 (en) * 2008-09-10 2011-07-07 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
WO2010043650A2 (en) * 2008-10-14 2010-04-22 Ablynx Nv Amino acid sequences directed against cellular receptors for viruses and bacteria
JP2012510806A (ja) 2008-12-08 2012-05-17 コンプリクス エン ヴェー 単鎖逆平行コイルドコイルタンパク質
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
NO2723764T3 (pl) 2011-09-15 2018-05-26
AU2014214054B2 (en) 2013-02-05 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Muscarinic acetylcholine receptor binding agents and uses thereof
AU2015217846B2 (en) 2014-01-30 2019-10-10 The Board Of Trustees Of The Leland Stanford Junior University Opioid receptor binding agents and uses thereof

Also Published As

Publication number Publication date
US12092646B2 (en) 2024-09-17
DK2593791T3 (en) 2017-02-06
EP3557255A1 (en) 2019-10-23
US20180100865A1 (en) 2018-04-12
CN103180734A (zh) 2013-06-26
US20190383827A1 (en) 2019-12-19
PT4273549T (pt) 2025-01-03
ES2771479T3 (es) 2020-07-06
DK3557254T3 (da) 2022-01-24
US20190049463A1 (en) 2019-02-14
EP2593791B1 (en) 2016-11-23
US20240103013A1 (en) 2024-03-28
US20200025773A1 (en) 2020-01-23
US9863959B2 (en) 2018-01-09
CA2805560A1 (en) 2012-01-19
BR112013001180B1 (pt) 2022-01-11
PL3557255T3 (pl) 2022-06-20
CN103180734B (zh) 2016-03-02
AU2011278244B8 (en) 2016-02-11
US10054598B2 (en) 2018-08-21
EP4273549A1 (en) 2023-11-08
BR112013001180A2 (pt) 2016-05-31
US10078088B2 (en) 2018-09-18
EP2593792B1 (en) 2019-11-13
PT2593792T (pt) 2020-01-29
WO2012007593A1 (en) 2012-01-19
US9453065B2 (en) 2016-09-27
US10436796B2 (en) 2019-10-08
PL3557254T3 (pl) 2022-05-23
EP3557254A1 (en) 2019-10-23
HUE031572T2 (en) 2017-07-28
AU2011278244A1 (en) 2013-02-28
HUE070205T2 (hu) 2025-05-28
AU2011278244A8 (en) 2016-02-11
EP2593791A1 (en) 2013-05-22
ES2907049T3 (es) 2022-04-21
EP3557256A1 (en) 2019-10-23
JP2021042209A (ja) 2021-03-18
US20190041400A1 (en) 2019-02-07
US20130137856A1 (en) 2013-05-30
ES2905455T3 (es) 2022-04-08
ES3007288T3 (en) 2025-03-19
PL4273549T3 (pl) 2025-03-03
PT2593791T (pt) 2017-02-01
JP6302248B2 (ja) 2018-03-28
US20190383828A1 (en) 2019-12-19
JP6859229B2 (ja) 2021-04-14
EP3557254B1 (en) 2021-12-15
ES2613532T3 (es) 2017-05-24
FI4273549T3 (fi) 2025-02-05
GB201014715D0 (en) 2010-10-20
WO2012007594A1 (en) 2012-01-19
JP2023085340A (ja) 2023-06-20
US20190383829A1 (en) 2019-12-19
EP2593792A1 (en) 2013-05-22
US20180067126A1 (en) 2018-03-08
EP3557255B1 (en) 2021-11-17
US20170153245A1 (en) 2017-06-01
JP2018027936A (ja) 2018-02-22
US9689872B2 (en) 2017-06-27
HRP20220326T1 (hr) 2022-05-13
JP7248637B2 (ja) 2023-03-29
EP3557257A1 (en) 2019-10-23
EP4273549B1 (en) 2024-11-06
HRP20170201T1 (hr) 2017-04-07
US11162953B2 (en) 2021-11-02
PT3557255T (pt) 2022-01-20
HRP20220204T1 (hr) 2022-04-29
US20130183287A1 (en) 2013-07-18
PL2593792T3 (pl) 2020-05-18
DK3557255T3 (da) 2022-01-24
DK4273549T3 (da) 2024-12-02
CA2805560C (en) 2019-10-29
JP2013536173A (ja) 2013-09-19
US20190383826A1 (en) 2019-12-19
US20190383825A1 (en) 2019-12-19
US20160347842A1 (en) 2016-12-01
PT3557254T (pt) 2022-01-20
AU2011278244B2 (en) 2016-01-28
US20220099683A1 (en) 2022-03-31
US11162954B2 (en) 2021-11-02
DK2593792T3 (da) 2020-02-03

Similar Documents

Publication Publication Date Title
PL3557254T3 (pl) Domeny wiążące białko stabilizujące funkcjonalne stany konformacyjne GPCR i ich zastosowania
EP2655415A4 (en) THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF
IL224523B (en) Mice producing binding proteins containing vl domains
PT2723764T (pt) Domínios de ligação dirigidos contra complexos gpcr:proteína g e suas utilizações derivadas
LT3040424T (lt) Modifikuoti baltymai ir jų gavimo ir panaudojimo būdai
DE102011009669B8 (de) Architektur zur robusten Kraft- und Impedanzsteuerung von seriellen elastischen Stellgliedern
IL214643A0 (en) Specific binding proteins and uses thereof
IL222961A0 (en) Novel dna-dinding proteins and uses thereof
IL223667B (en) 4a100s antibodies and medical uses thereof
EP2478005A4 (en) CROSSLINKED CRYSTALS AND CRYSTALS OF PROTEIN A AND METHODS OF USE THEREOF
PL2441774T3 (pl) Peptydy zawierające motywy palców cynkowych i ich zastosowania
EP2534258A4 (en) KINAEDOMÄNEN WITH DOUBLE ACTIVITY AND USES THEREOF
PL2627192T3 (pl) Hydrolizaty białek zwierzęcych pochodzenia morskiego o właściwościach neuroprotekcyjnych
EP2324058A4 (en) BIOLOGICAL APPLICATION OF STEROID-BINDING DOMAINS
AU2010900887A0 (en) Protein domains and uses therefor-II
AU2010900571A0 (en) Protein domains and uses therefor
HK1190416A (en) Tri-variable domain binding proteins and uses thereof
GB201005972D0 (en) Solubilisation of membrane proteins